linvesta-met xr 5/1000mg tablet
q pharma dmcc unit no: 2681 dmcc business centre level no. 1 - linagliptin 5mg + metformin hcl 1000mg tablet - tablet - linagliptin 5mg + metformin hcl 1000mg tablet - metformin and linagliptin
trajenta duo 2.5mg 500mg film-coated tablets
boehringer ingelheim (malaysia) sdn. bhd. - metformin hydrochloride; linagliptin -
trajenta duo 2.5mg 850mg film-coated tablets
boehringer ingelheim (malaysia) sdn. bhd. - metformin hydrochloride; linagliptin -
trajenta duo 2.5mg 1000mg film-coated tablets
boehringer ingelheim (malaysia) sdn. bhd. - metformin hydrochloride; linagliptin -
jentadueto 2.5mg1000mg tablets
boehringer ingelheim ltd - metformin hydrochloride; linagliptin - tablet - 1000mg ; 2.5mg
trajenta film-coated tablets 5mg
boehringer ingelheim singapore pte. ltd. - linagliptin - tablet, film coated - 5.000mg - linagliptin 5.000mg
qtrilmet
astrazeneca ab - metformin hydrochloride, saxagliptin, dapagliflozin - diabetes mellitus, type 2 - drugs used in diabetes - qtrilmet is indicated in adults aged 18 years and older with type 2 diabetes mellitus:to improve glycaemic control when metformin with or without sulphonylurea (su) and either saxagliptin or dapagliflozin does not provide adequate glycaemic control.when already being treated with metformin and saxagliptin and dapagliflozin.
glyxambi
boehringer ingelheim international gmbh - empagliflozin, linagliptin - diabetes mellitus, type 2 - drugs used in diabetes - glyxambi, fixed dose combination of empagliflozin and linagliptin, is indicated in adults aged 18 years and older with type 2 diabetes mellitus:to improve glycaemic control when metformin and/or sulphonylurea (su) and one of the monocomponents of glyxambi do not provide adequate glycaemic control;when already being treated with the free combination of empagliflozin and linagliptin.
synjardy
boehringer ingelheim - empagliflozin, metformin - diabetes mellitus, type 2 - drugs used in diabetes - synjardy is indicated in adults aged 18 years and older with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycaemic control:in patients inadequately controlled on their maximally tolerated dose of metformin alone;in patients inadequately controlled with metformin in combination with other glucose-lowering medicinal products, including insulin;in patients already being treated with the combination of empagliflozin and metformin as separate tablets.
glyxambi- empagliflozin and linagliptin tablet, film coated
boehringer ingelheim pharmaceuticals, inc. - empagliflozin (unii: hdc1r2m35u) (empagliflozin - unii:hdc1r2m35u), linagliptin (unii: 3x29zej4r2) (linagliptin - unii:3x29zej4r2) - empagliflozin 10 mg - glyxambi is a combination of empagliflozin and linagliptin indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. empagliflozin is indicated to reduce the risk of cardiovascular death in adults with type 2 diabetes mellitus and established cardiovascular disease [see clinical studies (14.2)] . limitations of use glyxambi is not recommended for use to improve glycemic control in patients with type 1 diabetes mellitus. it may increase the risk of diabetic ketoacidosis in these patients [see warnings and precautions (5.1)] . glyxambi has not been studied in patients with a history of pancreatitis. it is unknown whether patients with a history of pancreatitis are at an increased risk for the development of pancreatitis while using glyxambi [see warnings and precautions (5.2)]. glyxambi is not recommended for use to improve glycemic control in adults with type 2 diabetes mellitus with an egfr less than 30 ml/min/1.73 m2 . glyxambi is likely to be ineffecti